Imaging Genetics Synergy HealthLytix's mergers with CorTechs Labs and Cortechs.ai create an integrated platform that combines quantitative neuroimaging with genetic risk tools, enabling cross-sell opportunities to hospitals, radiology groups, and cancer centers through bundled offerings like RSI-MRI+ with genetic risk models.

Early Detection Focus With the RSI-MRI+ launch and a mission centered on early cancer and neurodegenerative disease detection, target buyers in radiology departments, oncology centers, and academic medical centers seeking cost-saving, early-intervention tools that improve patient outcomes.

Strategic Partnerships Leverage existing and historic partnerships and distribution agreements (CorTechs Labs, Dash Genomics) as a sales channel engine to reach new customers and expand market reach through co-marketing and joint solutions.

Mid-market Growth As a small to midsize player, HealthLytix can accelerate growth by targeting mid-market hospitals and imaging centers with scalable software deployments, pilot programs, and reference cases to demonstrate ROI.

Value Based Selling Position around cost containment and personalized risk assessment, using genetics-based Alzheimer's risk modeling and imaging analytics to support payer conversations and align with value-based care initiatives.